KR100671387B1 - 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도 - Google Patents

석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도 Download PDF

Info

Publication number
KR100671387B1
KR100671387B1 KR1020017008497A KR20017008497A KR100671387B1 KR 100671387 B1 KR100671387 B1 KR 100671387B1 KR 1020017008497 A KR1020017008497 A KR 1020017008497A KR 20017008497 A KR20017008497 A KR 20017008497A KR 100671387 B1 KR100671387 B1 KR 100671387B1
Authority
KR
South Korea
Prior art keywords
bone
radium
cancer
acid
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017008497A
Other languages
English (en)
Korean (ko)
Other versions
KR20010092772A (ko
Inventor
로이 에이취. 라센
제르문드 헨릭센
Original Assignee
안티-캔서 세라퓨틱 인벤션즈 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안티-캔서 세라퓨틱 인벤션즈 에이에스 filed Critical 안티-캔서 세라퓨틱 인벤션즈 에이에스
Publication of KR20010092772A publication Critical patent/KR20010092772A/ko
Application granted granted Critical
Publication of KR100671387B1 publication Critical patent/KR100671387B1/ko
Assigned to 바이엘 에이에스 reassignment 바이엘 에이에스 권리의 전부이전등록 Assignors: 알게타 에이에스에이
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
KR1020017008497A 1999-01-04 1999-12-17 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도 Expired - Fee Related KR100671387B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO19990001 1999-01-04
NO990001A NO310544B1 (no) 1999-01-04 1999-01-04 Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben

Publications (2)

Publication Number Publication Date
KR20010092772A KR20010092772A (ko) 2001-10-26
KR100671387B1 true KR100671387B1 (ko) 2007-01-19

Family

ID=19902803

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017008497A Expired - Fee Related KR100671387B1 (ko) 1999-01-04 1999-12-17 석회화된 조직을 표적으로 하는, 통증 완화, 뼈 암 치료,및 뼈 표면 조절용 라듐-223의 제조 및 용도

Country Status (24)

Country Link
US (2) US6635234B1 (enExample)
EP (1) EP1140212B1 (enExample)
JP (2) JP4649044B2 (enExample)
KR (1) KR100671387B1 (enExample)
CN (2) CN1194764C (enExample)
AT (1) ATE331534T1 (enExample)
AU (1) AU774991B2 (enExample)
BE (1) BE2014C028I2 (enExample)
BR (1) BR9916768A (enExample)
CA (1) CA2358498C (enExample)
CY (2) CY1105634T1 (enExample)
DE (1) DE69932183T2 (enExample)
DK (1) DK1140212T3 (enExample)
EA (1) EA003496B1 (enExample)
ES (1) ES2268888T3 (enExample)
IL (1) IL144135A0 (enExample)
LU (1) LU92425I2 (enExample)
MX (1) MXPA01006823A (enExample)
NO (2) NO310544B1 (enExample)
NZ (3) NZ534618A (enExample)
PT (1) PT1140212E (enExample)
TR (3) TR200201440T2 (enExample)
WO (1) WO2000040275A2 (enExample)
ZA (1) ZA200105431B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ307369B6 (cs) * 2016-12-22 2018-07-04 České vysoké učení technické v Praze Kombinace pro radionuklidovou terapii pro použití jako léčivo

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
AUPQ923100A0 (en) * 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
WO2003061566A2 (en) * 2002-01-24 2003-07-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anti-cancer combination and use thereof
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
ATE424221T1 (de) * 2003-04-30 2009-03-15 Univ Ramot Verfahren und vorrichtung für strahlentherapie
EA020542B1 (ru) * 2004-02-20 2014-12-30 Алгета Ас Альфа-излучающие частицы гидроксиапатита
DE102004022200B4 (de) * 2004-05-05 2006-07-20 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
US7914766B1 (en) * 2004-06-03 2011-03-29 Ut-Battelle Llc Inorganic resins for clinical use of 213Bi generators
GB0423565D0 (en) * 2004-10-22 2004-11-24 Algeta As Formulation
HUE037796T2 (hu) * 2005-07-26 2018-09-28 Aplha Tau Medical Ltd Radioaktív felületi forrás és eljárás elõállítására
US8709380B1 (en) * 2006-02-07 2014-04-29 Sirius Medicine, Llc Targeting agents for enhancing radiation therapy
DE102006008023B4 (de) 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
EP2796575B8 (en) * 2006-09-08 2020-04-01 Actinium Pharmaceuticals, Inc. Method for the purification of radium from different sources
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
GB201002508D0 (en) 2010-02-12 2010-03-31 Algeta As Product
GB201007353D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
GB201007354D0 (en) 2010-04-30 2010-06-16 Algeta Asa Method
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US20150343099A1 (en) 2012-12-19 2015-12-03 Bayer Pharma Aktiengesellschaft Combination comprising radium-223 for the treatment of cancer
GB201314718D0 (en) * 2013-08-16 2013-10-02 Algeta As Quantification method
WO2015082378A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN105934256B (zh) 2013-12-03 2019-12-27 拜耳制药股份公司 Pi3k-抑制剂的组合产品
SG11201604480PA (en) 2013-12-17 2016-07-28 Esteve Labor Dr SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
WO2016083739A1 (fr) 2014-11-26 2016-06-02 Rhodia Operations Composition de lanthane et d'actinium-227
GB201600153D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
GB201600154D0 (en) * 2016-01-05 2016-02-17 Bayer As Isotope preparation method
WO2018153969A1 (en) 2017-02-24 2018-08-30 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with radium-223 salt
SG11201910176PA (en) 2017-05-11 2019-11-28 Alpha Tau Medical Ltd Polymer coatings for brachytherapy devices
WO2019193464A1 (en) 2018-04-02 2019-10-10 Alpha Tau Medical Ltd. Controlled release of radionuclides
EP3563875A1 (en) * 2018-05-04 2019-11-06 Ceské vysoké ucení technické v Praze Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment
LU100900B1 (de) * 2018-08-10 2020-02-17 Thomas Melchior Homann Verbindungen zur modulation von a-ketoglutarsäure (2kg)-abhängigen oxygenasen
FR3086186B1 (fr) * 2018-09-26 2022-01-28 Orano Med Procede de production de plomb-212 a partir d'une solution aqueuse comprenant du thorium-228 et ses descendants
FR3088769B1 (fr) * 2018-11-15 2020-12-25 Orano Med Procede de preparation d'au moins un generateur a haute teneur en radium-228
WO2020180756A1 (en) * 2019-03-01 2020-09-10 Washington University Compositions and methods for radiotherapy using chelated radiotherapeutic agents and non-target tissue blockade
PH12022551370A1 (en) 2019-12-05 2023-05-08 Sciencons AS Production of highly purified 212pb
RU2752845C1 (ru) * 2020-05-13 2021-08-11 Акционерное Общество "Наука И Инновации" Способ получения высокочистого радия-223
IL303002B1 (en) 2020-12-16 2026-08-01 Alpha Tau Medical Ltd Radiation therapy using scattered alpha emitters with enhanced beta therapy
CN113066598B (zh) * 2021-03-25 2023-08-08 中国科学院近代物理研究所 一种从高能质子束辐照232Th靶引起的散裂反应中分离纯化223Ra的方法
US12042668B2 (en) 2021-06-10 2024-07-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for squamous cell carcinoma
US12064643B2 (en) 2021-06-10 2024-08-20 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for breast cancer
US11964168B2 (en) 2021-06-10 2024-04-23 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for prostate cancer
US12076581B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for glioblastoma
US12070620B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Activity levels for diffusing alpha-emitter radiation therapy
US12070621B2 (en) 2021-06-10 2024-08-27 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for pancreatic cancer
US12076582B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for colorectal cancer
US12076583B2 (en) 2021-06-10 2024-09-03 Alpha Tau Medical Ltd. Diffusing alpha-emitter radiation therapy for melanoma
JP2025507614A (ja) 2022-02-21 2025-03-21 バイエル・ヘルスケア・エルエルシー 治療薬または診断薬の送達のためのシステム、方法、およびデバイス
WO2023159230A1 (en) 2022-02-21 2023-08-24 Bayer Healthcare Llc System, method and device for delivery of a therapeutic or diagnostic agent
CN115869658B (zh) * 2022-12-29 2025-01-28 中国核动力研究设计院 用于制备Ra-223的分离系统及其分离方法、应用和制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH668489A5 (de) * 1982-01-22 1988-12-30 Vnii Mineralnogo Syrya Radiometrisches verfahren zur bestimmung der konzentration natuerlicher radiumisotope und einrichtung zur durchfuehrung des verfahrens.
AU626348B2 (en) * 1988-10-14 1992-07-30 Mallinckrodt, Inc. Radiolabelled particulate composition
US4970062A (en) * 1989-05-30 1990-11-13 The United States Of America As Represented By The United States Department Of Energy Colloid labelled with radionuclide and method
AU3177893A (en) * 1991-11-14 1993-06-15 Battelle Memorial Institute Method for diagnosing and treating cancer
AU683893B2 (en) * 1993-05-17 1997-11-27 Immunomedics Inc. Improved detection and therapy of lesions with biotin/avidin-metal chelating protein conjugates
US5809394A (en) * 1996-12-13 1998-09-15 Battelle Memorial Institute Methods of separating short half-life radionuclides from a mixture of radionuclides
US6117413A (en) * 1997-11-12 2000-09-12 Battelle Memorial Institute Radionuclide-binding compound, a radionuclide delivery system, a method of making a radium complexing compound, a method of extracting a radionuclide, and a method of delivering a radionuclide
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
NO314537B1 (no) * 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
NO312708B1 (no) * 2000-02-21 2002-06-24 Anticancer Therapeutic Inv Sa Radioaktive liposomer til terapi
NO313180B1 (no) * 2000-07-04 2002-08-26 Anticancer Therapeutic Inv Sa Bensökende alfapartikkel emitterende radiofarmasöytika
GB0213261D0 (en) * 2002-06-10 2002-07-17 Anticancer Therapeutic Inv Sa Method
GB0308731D0 (en) * 2003-04-15 2003-05-21 Anticancer Therapeutic Inv Sa Method of radiotherapy
US20060228297A1 (en) * 2003-04-15 2006-10-12 Roy Larsen Thorium-227 for use in radiotherapy of soft tissue disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ307369B6 (cs) * 2016-12-22 2018-07-04 České vysoké učení technické v Praze Kombinace pro radionuklidovou terapii pro použití jako léčivo

Also Published As

Publication number Publication date
TR200102707T2 (tr) 2002-03-21
MXPA01006823A (es) 2003-07-14
ES2268888T3 (es) 2007-03-16
DE69932183D1 (de) 2006-08-10
CN1335779A (zh) 2002-02-13
KR20010092772A (ko) 2001-10-26
LU92425I2 (fr) 2014-06-10
CA2358498C (en) 2008-09-16
JP5433490B2 (ja) 2014-03-05
PT1140212E (pt) 2006-11-30
CN1767078B (zh) 2012-01-11
CY1105634T1 (el) 2010-12-22
NZ513135A (en) 2004-09-24
DE69932183T2 (de) 2007-05-16
BE2014C028I2 (enExample) 2019-03-05
TR200201442T2 (tr) 2002-08-21
ZA200105431B (en) 2002-07-02
CY2014020I2 (el) 2015-12-09
JP2002534399A (ja) 2002-10-15
JP2010168397A (ja) 2010-08-05
CA2358498A1 (en) 2000-07-13
JP4649044B2 (ja) 2011-03-09
EA003496B1 (ru) 2003-06-26
CN1194764C (zh) 2005-03-30
EA200100642A1 (ru) 2002-02-28
ATE331534T1 (de) 2006-07-15
TR200201440T2 (tr) 2002-08-21
EP1140212A2 (en) 2001-10-10
DK1140212T3 (da) 2006-10-09
HK1090750A1 (en) 2006-12-29
NZ545023A (en) 2007-08-31
NO2014010I1 (no) 2014-06-02
AU774991B2 (en) 2004-07-15
US20030206857A1 (en) 2003-11-06
NO310544B1 (no) 2001-07-23
US6635234B1 (en) 2003-10-21
BR9916768A (pt) 2001-12-04
AU1700400A (en) 2000-07-24
NO990001D0 (no) 1999-01-04
CN1767078A (zh) 2006-05-03
WO2000040275A3 (en) 2001-06-21
NO2014010I2 (enExample) 2014-05-09
NZ534618A (en) 2006-03-31
NO990001L (no) 2000-07-05
EP1140212B1 (en) 2006-06-28
CY2014020I1 (el) 2015-12-09
IL144135A0 (en) 2002-05-23
WO2000040275A2 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
US6635234B1 (en) Preparation and use of radium-223 to target calcified tissues for pain palliation, bone cancer therapy, and bone surface conditioning
Washiyama et al. 227Th-EDTMP: a potential therapeutic agent for bone metastasis
Ando et al. Production of 105Rh–EDTMP and its bone accumulation
US10596277B2 (en) High purity therapeutic bone agents
JP2025036436A (ja) 治療用骨剤の使用方法
Tishchenko et al. The influence of carrier addition on the biodistribution of bone-seeking agent «188Re-oxa-bis (ethylenenitrilo)-tetramethylenephosphonic acid»
HK1090750B (en) Methods of preparing radium-223, and pharmaceutically acceptable agents and reagent set
NO317110B1 (no) Nytt radiofarmasoytisk preparat

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 7

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20131218

Year of fee payment: 8

PR1001 Payment of annual fee

Fee payment year number: 8

St.27 status event code: A-4-4-U10-U11-oth-PR1001

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000

S17-X000 Non-exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S17-lic-X000

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 6, Claim Number : 6, 7, 8, 10, 13 14, Period Limitation Text : 85, Comment Text : 5018

St.27 status event code: A-4-4-G10-G18-tex-PA0101

FPAY Annual fee payment

Payment date: 20141218

Year of fee payment: 9

PR1001 Payment of annual fee

Fee payment year number: 9

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20160104

Year of fee payment: 10

PR1001 Payment of annual fee

Fee payment year number: 10

St.27 status event code: A-4-4-U10-U11-oth-PR1001

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20170102

Year of fee payment: 11

PR1001 Payment of annual fee

Fee payment year number: 11

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PE0702 Decision to register extension of term of patent right by permit, etc.

Protection beyond ip right term event data comment text: Claim Total Quantity : 6, Claim Number : 6, 7, 8, 10, 13 14, Period Limitation Text : 85, Comment Text : 5018

St.27 status event code: A-4-4-G10-G20-tex-PE0702

FPAY Annual fee payment

Payment date: 20180103

Year of fee payment: 12

PR1001 Payment of annual fee

Fee payment year number: 12

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20190103

Year of fee payment: 13

PR1001 Payment of annual fee

Fee payment year number: 13

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20200113

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200113

St.27 status event code: N-4-6-H10-H13-oth-PC1903